Evidence map›Paper›PMID 27911295›Full record

Trial reportJournal of Alzheimer's disease : JAD2017

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.

Mercè Boada, Fernando Anaya, Pilar Ortiz, Javier Olazarán, Joshua R Shua-Haim, Thomas O Obisesan, Isabel Hernández, Joan Muñoz, Mar Buendia, Montserrat Alegret and 8 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Research progress on blood therapy for anti-aging.Journal of advanced research · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Prognostic value of plasma Aβ1-40 for Alzheimer's disease.American journal of translational research · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Mercè BoadaMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Fernando AnayaNephrology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Pilar OrtizBanc de Sang i Teixits, Barcelona, Spain.
Javier OlazaránNeurology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Joshua R Shua-HaimAlzheimer's Research Corporation, Mid Atlantic Geriatric Association, Manchester, NJ, USA.
Thomas O ObisesanDepartment of Internal Medicine, Howard University, Washington, DC, USA.
Isabel HernándezMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Joan MuñozBanc de Sang i Teixits, Barcelona, Spain.
Mar BuendiaMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Montserrat AlegretMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Asunción LafuenteMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Lluís TárragaMemory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain.
Laura NúñezClinical Trials Department, Instituto Grifols S.A., Barcelona, Spain.
Mireia TorresClinical Trials Department, Instituto Grifols S.A., Barcelona, Spain.
Joan Ramon GrifolsBanc de Sang i Teixits, Barcelona, Spain.
Isidre FerrerInstitut de Neuropatologia, Hospital Universitario Bellvitge, Barcelona, Spain.
Oscar L LopezDepartments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA.
Antonio PáezClinical Trials Department, Instituto Grifols S.A., Barcelona, Spain.
Fundació ACE · ESBanc de Sang i Teixits · ESGrifols (Spain) · ESHospital General Universitario Gregorio Marañón · ESAlzheimer's Association · USBellvitge University Hospital · ESHoward University · USUniversity of Pittsburgh · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
NCATS NIH HHS UL1 TR001409
6 · The paper itself

Abstract

backgroundStudies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments.

objectiveTo determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer's disease (AD).

methodsIn a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ1-40 and Aβ1-42 levels, as well as cognitive, functional, and behavioral measures were determined.

resultsCSF Aβ1-42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus -45.5 pg/mL; 95% CI: -19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ1-42 levels were lower in the PE-treated group after each treatment period (p < 0.05). Plasma Aβ1-40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency (p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase (p < 0.05).

conclusionPE with human albumin modified CSF and plasma Aβ1-42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.

Indexed as

AgedAged, 80 and overAlbuminsAlzheimer DiseaseAmyloid beta-PeptidesCognition DisordersFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsPlasma ExchangePsychiatric Status Rating ScalesTomography Scanners, X-Ray ComputedAlbuminsAmyloid beta-PeptidesAlbuminAlzheimer’s diseaseCSF Aβplasma Aβplasma exchange

Identifiers

PMID27911295
PMCPMC5240541
OpenAlexW2559487414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.